Developmental and Epileptic Encephalopathy (DEE)

1. Developmental and Epileptic Encephalopathy (DEE) Market Report 2032 | DelveInsight DelveInsight's "Developmental and Epileptic Encephalopathy (DEE) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Developmental and Epileptic Encephalopathy (DEE), historical and forecasted epidemiology, and the Developmental and Epileptic Encephalopathy (DEE) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Developmental and Epileptic Encephalopathy (DEE) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Developmental and Epileptic Encephalopathy (DEE) market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Developmental and Epileptic Encephalopathy (DEE) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Developmental and Epileptic Encephalopathy (DEE) market. Developmental and Epileptic Encephalopathy (DEE): An Overview Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as

2. well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills. The syndromes of epileptic encephalopathies with onset in the neonatal period, infancy, and early childhood include early myoclonic encephalopathy, Ohtahara syndrome, West syndrome, Dravet syndrome (severe myoclonic epilepsy in infancy), Lennox–Gastaut syndrome (LGS), Landau–Kleffner syndrome (LKS), Epilepsy with continuous spike-and-waves during slow-wave sleep, Doose Syndrome (myoclonic atonic epilepsy), CDKL5 deficiency disorder (CDD), Tuberous sclerosis complex (TSC), SCN8A-DEE, and KCNQ2-DEE. Learn about Developmental and Epileptic Encephalopathy (DEE), different geographies treatment algorithms, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/developmental-and- epileptic-encephalopathies-dee-market Developmental and Epileptic Encephalopathy (DEE) Market The Developmental and Epileptic Encephalopathy (DEE) market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Developmental and Epileptic Encephalopathy (DEE) market trends by analyzing the impact of current Developmental and Epileptic Encephalopathy (DEE) therapies on the market and unmet needs, drivers and barriers, and demand for better technology. Currently, the commonly used treatment therapy is antiepileptic medications. The early treatment choice for almost all patients with multiple seizures is AEDs. The medications treat the symptoms of epilepsy (the seizures) and are highly effective and completely control seizures in the majority (70%) of cases. The drugs prevent seizures from starting by reducing brain cells’ tendency to send excessive and confused electrical signals. Choice of medication depends on a variety of factors, some of which include the type of seizure and type of epilepsy, the likely side effects of the medication, other medical conditions the patient may have, potential interactions with the patient’s other medications, age, gender and cost of the medication. Anticonvulsant therapy is also considered after two unprovoked epileptic seizures. The medication prescribed by the medical practitioner could be monotherapy or a combinational therapy, including two or more products as a medication. Out of the above-mentioned syndromes of epileptic encephalopathies, infants are majorly affected by LGS and Dravet Syndrome. The three main forms of treatment for LGS and Dravet Syndrome are antiepileptic drugs (AEDs), dietary therapy (typically the ketogenic diet), or device/surgery (VNS therapy or corpus callosotomy). Valproate (Valproic acid) is one of the most useful initial medications of choice to control absence seizures, tonic-

3. clonic seizures (grand mal), complex partial seizures, juvenile myoclonic epilepsy, and the seizures associated with LGS. Valproate is considered the first line of therapy for LGS as it is effective against a wide spectrum of seizures. The drug is administered as a monotherapy, and if ineffective, another drug such as lamotrigine, topiramate rufinamide, or clobazam may be added. It also has significant side effects ranging from tremors to reduction in platelet count and function as well as hyperammonemia. The market size of DEE in the 7MM is expected to rise from USD 957 million in 2019 at a CAGR of 15.5% during the study period (2019–2032). According to DelveInsight, the Developmental and Epileptic Encephalopathy (DEE) market in 7MM is expected to witness a major change in the study period 2019-2032. Request a sample and discover more about the report offerings at: https://www.delveinsight.com/sample-request/developmental-and-epileptic- encephalopathies-dee-market Developmental and Epileptic Encephalopathy (DEE) Epidemiology The Developmental and Epileptic Encephalopathy (DEE) epidemiology section provides insights into the historical and current Developmental and Epileptic Encephalopathy (DEE) patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Developmental and Epileptic Encephalopathy (DEE) market report also provides the diagnosed patient pool, trends, and assumptions. Developmental and Epileptic Encephalopathy (DEE) Assessment The dynamics of the Developmental and Epileptic Encephalopathy (DEE) Infection market are anticipated to change in the coming years. The potential therapies expected to be launched in the forecast period include XEN496, Carisbamate, TAK-935, EPX-100, and others. The launch of these therapies may increase market size in the coming years. Developmental and Epileptic Encephalopathy (DEE) Therapeutics Assessment Emerging Therapy

4. Major key companies such as Jazz Pharmaceuticals, Biocodex, Zogenix, Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, and many others are working proactively in the Developmental and Epileptic Encephalopathy (DEE) Therapeutics market to develop novel therapies which will drive the Developmental and Epileptic Encephalopathy (DEE) treatment markets in the upcoming years. Developmental and Epileptic Encephalopathy (DEE) Report Key Insights 1. Developmental and Epileptic Encephalopathy (DEE) Patient Population 2. Developmental and Epileptic Encephalopathy (DEE) Market Size and Trends 3. Key Cross Competition in the Developmental and Epileptic Encephalopathy (DEE) Market 4. Developmental and Epileptic Encephalopathy (DEE) Market Dynamics (Key Drivers and Barriers) 5. Developmental and Epileptic Encephalopathy (DEE) Market Opportunities 6. Developmental and Epileptic Encephalopathy (DEE) Therapeutic Approaches 7. Developmental and Epileptic Encephalopathy (DEE) Pipeline Analysis 8. Developmental and Epileptic Encephalopathy (DEE) Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Developmental and Epileptic Encephalopathy (DEE) Market Table of Contents 1. Key Insights 2. Executive Summary 3. Developmental and Epileptic Encephalopathy (DEE) Competitive Intelligence Analysis 4. Developmental and Epileptic Encephalopathy (DEE) Market Overview at a Glance 5. Developmental and Epileptic Encephalopathy (DEE) Disease Background and Overview 6. Developmental and Epileptic Encephalopathy (DEE) Patient Journey 7. Developmental and Epileptic Encephalopathy (DEE) Epidemiology and Patient Population 8. Developmental and Epileptic Encephalopathy (DEE) Treatment Algorithm, Current Treatment, and Medical Practices 9. Developmental and Epileptic Encephalopathy (DEE) Unmet Needs 10. Key Endpoints of Developmental and Epileptic Encephalopathy (DEE) Treatment 11. Developmental and Epileptic Encephalopathy (DEE) Marketed Products

5. 12. Developmental and Epileptic Encephalopathy (DEE) Emerging Therapies 13. Developmental and Epileptic Encephalopathy (DEE) Seven Major Market Analysis 14. Attribute Analysis 15. Developmental and Epileptic Encephalopathy (DEE) Market Outlook (7 major markets) 16. Developmental and Epileptic Encephalopathy (DEE) Access and Reimbursement Overview 17. KOL Views on the Developmental and Epileptic Encephalopathy (DEE) Market 18. Developmental and Epileptic Encephalopathy (DEE) Market Drivers 19. Developmental and Epileptic Encephalopathy (DEE) Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer Get the Detailed TOC of the Developmental and Epileptic Encephalopathy (DEE) Market report here: https://www.delveinsight.com/report-store/developmental- and-epileptic-encephalopathies-dee-market About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Contact Us: Kritika Rehani krehani@delveinsight.com info@delveinsight.com +1(919)321-6187 www.delveinsight.com